Abstract Purpose: The aim of this study was to characterize the frequency of adverse effects where delta-8 tetrahydrocannabinol (D8-THC) was…
Abstract Background: Opioids continue to be widely prescribed for chronic noncancer pain, despite the awareness that opioids provide only short-time…
Abstract Purpose of review: Prescribed and non-prescribed cannabis use is common. Providers in specialties treating chronic pain – primary care,…
Abstract (1) Background: With the massive demand for the use and commercialization of medicinal cannabidiol (CBD) products, new randomized clinical…
Abstract Objectives: Understanding gender differences in chronic pain (CP) outcome research is essential to optimal treatment delivery. This study explored…
Abstract Cannabidiol (CBD), a major non-psychotropic component of cannabis, is receiving growing attention as a potential anticancer agent. CBD suppresses…
Abstract Since late 2019, low‐delta‐9‐tetrahydrocannabinol (THC) preparations adulterated with synthetic cannabinoids (SCs) have been frequently observed in Switzerland. The unawareness…
Abstract Dronabinol, a natural cannabinoid, and its semi-synthetic derivative, nabilone, are marketed as medicines in several countries. The aim of…
Abstract Ulcerative colitis (UC) is an idiopathic, chronic inflammatory disease with multiple genetic and a variety of environmental risk factors.…
Abstract Background: Cannabis has been rapidly legalized in North America; however, limited evidence exists around its side effects. Health Canada…